2023 Q2 Form 10-K Financial Statement

#000101738623000145 Filed on April 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q4 2022
Revenue $17.55K $21.13K $46.80K
YoY Change 124.91% 369.56% 56.01%
Cost Of Revenue $4.732K $5.710K $12.67K
YoY Change 128.82% 335.88% 26.74%
Gross Profit $12.82K $15.42K $34.13K
YoY Change 123.5% 383.39% 70.65%
Gross Profit Margin 73.04% 72.98% 72.92%
Selling, General & Admin $112.6K $209.7K $504.3K
YoY Change 8.6% 479.46% 320.27%
% of Gross Profit 878.14% 1359.6% 1477.69%
Research & Development $5.876K $3.120K $12.07K
YoY Change 10.83% -56.49% 20.74%
% of Gross Profit 45.84% 20.23% 35.38%
Depreciation & Amortization $240.00 $220.00 $536.00
YoY Change 118.18%
% of Gross Profit 1.87% 1.43% 1.57%
Operating Expenses $118.4K $212.8K $516.4K
YoY Change 8.7% 390.82% 297.22%
Operating Profit -$105.6K -$197.4K -$482.3K
YoY Change 2.33% 391.41% 338.42%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $530.00 -$310.00 $1.340K
YoY Change -56.56%
Pretax Income -$105.1K -$197.7K -$480.9K
YoY Change 3.03% 392.3% 337.21%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$105.1K -$197.7K -$480.9K
YoY Change 3.03% 392.3% 342.38%
Net Earnings / Revenue -598.78% -935.45% -1027.55%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 111.9M shares 111.8M shares 111.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.52K $138.3K $138.3K
YoY Change -94.66% -35.37% -34.13%
Cash & Equivalents $10.52K $138.3K
Short-Term Investments
Other Short-Term Assets $1.170K $30.67K $30.67K
YoY Change
Inventory $16.40K $27.55K $27.55K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $28.09K $196.5K $196.5K
YoY Change -87.9% -22.62% -21.38%
LONG-TERM ASSETS
Property, Plant & Equipment $3.978K $4.470K $4.470K
YoY Change 20.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.978K $4.470K $4.470K
YoY Change 20.22%
TOTAL ASSETS
Total Short-Term Assets $28.09K $196.5K $196.5K
Total Long-Term Assets $3.978K $4.470K $4.470K
Total Assets $32.07K $201.0K $201.0K
YoY Change -86.39% -20.86% -19.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.30K $1.565K $1.570K
YoY Change 1421.69% 34.91%
Accrued Expenses $11.06K $13.19K $10.83K
YoY Change 2.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $55.69K $25.59K $25.59K
YoY Change 281.99% 631.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $55.69K $25.59K $25.59K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $55.69K $25.59K $25.59K
YoY Change 281.99% 631.8%
SHAREHOLDERS EQUITY
Retained Earnings -$1.156M -$936.7K
YoY Change 87.24% 105.53%
Common Stock $86.85K $111.8K
YoY Change -22.28% -1.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$23.63K $175.4K $175.4K
YoY Change
Total Liabilities & Shareholders Equity $32.07K $201.0K $201.0K
YoY Change -86.39% -20.86% -19.6%

Cashflow Statement

Concept 2023 Q2 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$105.1K -$197.7K -$480.9K
YoY Change 3.03% 392.3% 342.38%
Depreciation, Depletion And Amortization $240.00 $220.00 $536.00
YoY Change 118.18%
Cash From Operating Activities -$39.45K -$68.72K -$301.9K
YoY Change -49.18% 79.14% 201.89%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $1.280K $5.820K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$1.280K -$5.818K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $225.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 102.0K $232.0K
YoY Change -100.0% 10100.0% 5.46%
NET CHANGE
Cash From Operating Activities -39.45K -68.72K -301.9K
Cash From Investing Activities 0.000 -1.280K -$5.818K
Cash From Financing Activities 0.000 102.0K $232.0K
Net Change In Cash -39.45K 32.00K -$75.71K
YoY Change -221.57% -185.65% -163.09%
FREE CASH FLOW
Cash From Operating Activities -$39.45K -$68.72K -$301.9K
Capital Expenditures $0.00 $1.280K $5.820K
Free Cash Flow -$39.45K -$70.00K -$307.7K
YoY Change -46.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001703157
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Deposit Assets
DepositAssets
usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021 scth Cancellation Of Common Shares
CancellationOfCommonShares
usd
CY2022 scth Cancellation Of Common Shares
CancellationOfCommonShares
usd
CY2021 us-gaap Depreciation
Depreciation
usd
CY2021 scth Gain Loss On Disposition Of Assets2
GainLossOnDispositionOfAssets2
usd
CY2021 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
usd
CY2021 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
usd
CY2021 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
usd
CY2021 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
usd
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-55927
CY2022 dei Entity Registrant Name
EntityRegistrantName
SecureTech Innovations, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-0972782
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
2355 Highway 36 West
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Roseville
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55113
CY2022 dei City Area Code
CityAreaCode
(651) 317-8990
CY2022 dei Local Phone Number
LocalPhoneNumber
317-8990
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
31749800 usd
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
111850513 shares
CY2022 dei Auditor Name
AuditorName
M&K CPAS, PLLC
CY2022 dei Auditor Firm
AuditorFirmId
2738
CY2022 dei Auditor Location
AuditorLocation
Houston, TX
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
138318 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
214026 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
27549 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
39975 usd
CY2022Q4 us-gaap Deposit Assets
DepositAssets
30674 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
196541 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
254001 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4470 usd
CY2022Q4 us-gaap Assets
Assets
201011 usd
CY2021Q4 us-gaap Assets
Assets
254001 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1565 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1160 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13194 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5679 usd
CY2022Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
5153 usd
CY2021Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2337 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25591 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3497 usd
CY2022Q4 us-gaap Liabilities
Liabilities
25591 usd
CY2021Q4 us-gaap Liabilities
Liabilities
3497 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111839085 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
111839085 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
113336300 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
113336300 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
111839 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
113336 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1000239 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
592899 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-936658 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-455731 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
175420 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
250504 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
201011 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
254001 usd
CY2022 us-gaap Revenues
Revenues
46803 usd
CY2021 us-gaap Revenues
Revenues
31713 usd
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12674 usd
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8915 usd
CY2022 us-gaap Gross Profit
GrossProfit
34129 usd
CY2021 us-gaap Gross Profit
GrossProfit
22798 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
504316 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
124267 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12074 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7245 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
516390 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
131511 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-482261 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-108713 usd
CY2022 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1335 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-480926 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-108713 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111929796 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
156034210 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
135967 usd
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
222250 usd
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.20
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1000 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-108713 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
250504 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
225001 usd
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.50
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7000 usd
CY2022 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
173842 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-480927 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
175420 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-480926 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-108713 usd
CY2022 us-gaap Depreciation
Depreciation
536 usd
CY2022 scth Gain Loss On Disposition Of Assets2
GainLossOnDispositionOfAssets2
812 usd
CY2022 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
173842 usd
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12426 usd
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9018 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
405 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-175 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
13194 usd
CY2022 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
5679 usd
CY2022 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-30674 usd
CY2022 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
2816 usd
CY2021 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
842 usd
CY2022 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-301891 usd
CY2021 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-99028 usd
CY2022 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
5818 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5818 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
225001 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
222250 usd
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7000 usd
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
232001 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
223250 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-75708 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
124222 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
214026 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89804 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138318 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
214026 usd
CY2022 scth Stock Cancelled1
StockCancelled1
1700 usd
CY2021 scth Stock Cancelled1
StockCancelled1
58000 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_z2y1ugT9Tdj" style="font: 10pt Times New Roman; margin: 0; text-align: justify"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify">The accompanying financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America.  Because a precise determination of many assets and liabilities depends on future events, the preparation of financial statements for a period necessarily involves the use of estimates made using careful judgment.  Actual results may vary from these estimates.</p> <hr style="border-width: 0; margin: 14pt 0 0; height: 0; width: 0"/>
CY2022 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.762 pure
CY2022 us-gaap Fiscal Period
FiscalPeriod
<p id="xdx_846_eus-gaap--FiscalPeriod_ziGDDIqDI7z4" style="font: 10pt Times New Roman; margin: 0; text-align: justify"><b>Fiscal Year</b></p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify">The Company elected December 31st for its fiscal year-end.</p> <p style="font: 10pt Times New Roman; margin: 0"> </p>
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-936658 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
196698 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
95704 usd
CY2022Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2185 usd
CY2021Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
1955 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
25364 usd
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
38020 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
27549 usd
CY2021Q4 us-gaap Inventory Gross
InventoryGross
39975 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
27549 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
39975 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
196698 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
95704 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
936658 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
188785 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
225001 usd
CY2022 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
14000 shares
CY2022 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
14000 shares
CY2022 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
7000 usd
CY2022 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1700000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
111839085 shares
CY2022 scth Warrants Disclosure
WarrantsDisclosure
<p id="xdx_802_ecustom--WarrantsDisclosure_zqBELsV8MK57" style="font: 10pt Times New Roman; margin: 0; text-align: justify"><b>NOTE 6 – WARRANTS</b></p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify">As of December 31, 2022, the Company had no warrants issued and outstanding.</p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify; color: #000000"><i>Warrant Issuances, Exercises, and Expirations</i></p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify; color: #000000"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify; color: #000000">Private Placement Warrant Issuances</p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify; color: #000000"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify; color: #000000">During the fiscal year ended December 31, 2020, the Company undertook a private placement of its securities through a private placement Unit offering. Each Unit included one share of the Company’s common stock and four stock purchase warrants with incremental exercise prices and expiration dates. An aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231_zmsE7pek1Dz9">1,757,200</span> stock purchase warrants were issued under this offering, which was closed on June 30, 2020.</p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify; color: #000000"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify; color: #000000">The warrants were valued using the Black-Scholes model with a <span id="xdx_905_eus-gaap--AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherFairValueVolatilityRate_dp_c20210101__20211231_znTpA2mtlcF4">53.0%</span> volatility rate and discount rates ranging from<span id="xdx_90C_ecustom--DiscountRateMinimum_dp_c20210101__20211231_zLeheOjnsDIl"> 0.16%</span> - <span id="xdx_900_ecustom--DiscountRateMaximum_dp_c20210101__20211231_zYfHRXAhuLce">0.21%</span> for a total fair value of $<span id="xdx_906_eus-gaap--WarrantsNotSettleableInCashFairValueDisclosure_iI_c20211231_zvZx5r2ehiac">19,257</span>.</p> <p style="font: 10pt Times New Roman; margin: 0; color: #000000"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify; color: #000000">Warrant Expirations</p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify; color: #000000"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify; color: #000000">During the fiscal year ended December 31, 2022, an aggregate of 1,303,900 warrants expired with an average exercise price of $0.35 a share.</p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify; color: #000000"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify">A summary of the warrant activity for the fiscal year ended December 31, 2022, is as follows:</p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfStockholdersEquityNoteWarrantsActivityTextBlock_za0pSIaa41ek" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants Activity (Details)"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center"><b style="display: none">Warrant Activity</b></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman; margin: 0; text-align: center"> </p><p style="font: 10pt Times New Roman; margin: 0; text-align: center"> </p><p style="font: 10pt Times New Roman; margin: 0; text-align: center"> </p><p style="font: 10pt Times New Roman; margin: 0; text-align: center"><b>Weighted-Average</b></p> <p style="font: 10pt Times New Roman; margin: 0; text-align: center"><b>Exercise Price</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman; margin: 0; text-align: center"><b>Weighted-Average</b></p> <p style="font: 10pt Times New Roman; margin: 0; text-align: center"><b>Remaining</b></p> <p style="font: 10pt Times New Roman; margin: 0; text-align: center"><b>Contractual Term</b></p> <p style="font: 10pt Times New Roman; margin: 0; text-align: center"><b>(Years)</b></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman; margin: 0; text-align: center"> </p><p style="font: 10pt Times New Roman; margin: 0; text-align: center"> </p><p style="font: 10pt Times New Roman; margin: 0; text-align: center"> </p><p style="font: 10pt Times New Roman; margin: 0; text-align: center"> </p><p style="font: 10pt Times New Roman; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman; margin: 0; text-align: center"><b>Intrinsic Value</b></p></td></tr> <tr id="xdx_40D_ecustom--ClassOfWarrantNumberOfSharesAbstract_iB_zKyFZPDpaWYg" style="display: none; vertical-align: bottom"> <td colspan="3" style="text-align: justify"><b>Warrants</b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td></tr> <tr id="xdx_407_ecustom--ClassOfWarrantWeightedAverageExercisePriceAbstract_iB_zktaR7721s2a" style="display: none; vertical-align: bottom"> <td colspan="3" style="text-align: justify"><b>Weighted-Average Exercise Prices</b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td></tr> <tr id="xdx_40A_ecustom--ClassOfWarrantWeightedAverageRemainingContractualTermAbstract_iB_zAIbLEERpKG3" style="display: none; vertical-align: bottom"> <td colspan="3" style="text-align: justify"><b>Weighted-Average Remaining Contractual Term (Years)</b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td><td><b> </b></td> <td colspan="3" style="text-align: right"><b> </b></td></tr> <tr id="xdx_408_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_iB_z4NurxYEh32i" style="display: none; vertical-align: bottom"> <td colspan="3" style="text-align: justify"><b>Aggregate Intrinsic Value</b></td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: justify"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><p style="font: 10pt Times New Roman; margin: 0; text-align: justify">Outstanding on January 1, 2022</p></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iSP1custom--ClassOfWarrantNumberOfSharesAbstract_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zCuY2lutdOC" style="width: 16%; text-align: right">1,317,900</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--TemporaryEquityRedemptionPricePerShare_iSP1custom--ClassOfWarrantWeightedAverageExercisePriceAbstract_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQfThhVgIon5" style="width: 16%; text-align: right">0.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_iP1custom--ClassOfWarrantWeightedAverageRemainingContractualTermAbstract_dtY_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zDWgWdqNmyBl" style="width: 15%; text-align: right" title="Weighted-Average Remaining Contractual Term, beginning">0.3</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iSP1us-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSXGnOCwlDK" style="width: 15%; text-align: right">1,124,465</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman; margin: 0; text-align: justify">Issued</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--WarrantsIssuedDuringPeriod_iP1custom--ClassOfWarrantNumberOfSharesAbstract_d0_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ze1SYpa6kD87" style="text-align: right" title="Issued">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--WarrantsGrantedDuringPeriod_iP1custom--ClassOfWarrantWeightedAverageExercisePriceAbstract_d0_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zUPp3cqgfanl" style="text-align: right" title="Issued">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman; margin: 0; text-align: justify">Exercised</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--WarrantsExcercisedDuringPeriod_iP1custom--ClassOfWarrantNumberOfSharesAbstract_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zvDGXPnCD6e1" style="text-align: right" title="Exercised">(14,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--WarrantsExercisedDuringPeriod_iP1custom--ClassOfWarrantWeightedAverageExercisePriceAbstract_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0ZPHGvOSSLh" style="text-align: right" title="Exercised">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_iP1us-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zt9c1L7G4Ak" style="text-align: right">42,700</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman; margin: 0; text-align: justify">Expired</p></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--WarrantsCanceledDuringPeriod_iP1custom--ClassOfWarrantNumberOfSharesAbstract_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlO6BqloCtLa" style="border-bottom: Black 1pt solid; text-align: right" title="Expired">(1,303,900</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_ecustom--WarrantsForfeitedcanceledDuringPeriod_iP1custom--ClassOfWarrantWeightedAverageExercisePriceAbstract_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zEBW4ptPUdZ6" style="border-bottom: Black 1pt solid; text-align: right" title="Expired">0.35</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_iP1us-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zoicUeG8QASe" style="border-bottom: Black 1pt solid; text-align: right" title="Expired"> 4,172,480</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman; margin: 0; text-align: justify">Outstanding on December 31, 2022</p></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iEP1custom--ClassOfWarrantNumberOfSharesAbstract_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPst6QjbxKyf" style="border-bottom: Black 2.5pt double; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl0439">—</span>  </b></td><td style="padding-bottom: 2.5pt; text-align: left"><b> </b></td><td style="padding-bottom: 2.5pt"><b> </b></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><b> </b></td><td id="xdx_987_eus-gaap--TemporaryEquityRedemptionPricePerShare_iEP1custom--ClassOfWarrantWeightedAverageExercisePriceAbstract_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBExZxiEHrzf" style="border-bottom: Black 2.5pt double; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl0440">—</span>  </b></td><td style="padding-bottom: 2.5pt; text-align: left"><b> </b></td><td style="padding-bottom: 2.5pt"><b> </b></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><b> </b></td><td id="xdx_98C_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTermEnd_iP1custom--ClassOfWarrantWeightedAverageRemainingContractualTermAbstract_dtY_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zCAlEKqeVWxh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Remaining Contractual Term, ending"><span style="-sec-ix-hidden: xdx2ixbrl0442"><b>—  </b></span></td><td style="padding-bottom: 2.5pt; text-align: left"><b> </b></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iEP1us-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zcn03HJtHPA6" style="border-bottom: Black 2.5pt double; text-align: right"><b><span style="-sec-ix-hidden: xdx2ixbrl0443">—</span>  </b></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman; margin: 0; text-align: justify">The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of <span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20221231_zbNIUmxcslwk">$3.55</span> (based on the closing price quoted on the OTC Pink Tier of the OTC Market Group, Inc.) on December 31, 2022, which the warrant holders would have received had those warrant holders exercised their warrants as of that date.</p> <p style="font: 10pt Times New Roman; margin: 0"> </p>
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1757200 shares
CY2021 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Other Fair Value Volatility Rate
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherFairValueVolatilityRate
0.530 pure
CY2021 scth Discount Rate Minimum
DiscountRateMinimum
0.0016 pure
CY2021 scth Discount Rate Maximum
DiscountRateMaximum
0.0021 pure
CY2021Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
19257 usd
CY2022Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
3.55
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1500000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.35
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
3.160 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
0.028 pure
CY2022 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
173842 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
11428 shares
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
20000 usd
CY2023Q1 us-gaap Share Price
SharePrice
1.75

Files In Submission

Name View Source Status
0001017386-23-000145-index-headers.html Edgar Link pending
0001017386-23-000145-index.html Edgar Link pending
scth-20221231_def.xml Edgar Link unprocessable
0001017386-23-000145.txt Edgar Link pending
0001017386-23-000145-xbrl.zip Edgar Link pending
ex211.htm Edgar Link pending
ex311.htm Edgar Link pending
ex312.htm Edgar Link pending
ex321.htm Edgar Link pending
ex322.htm Edgar Link pending
ex41.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
scth-20221231.xsd Edgar Link pending
scth_form10k12312022.htm Edgar Link pending
Show.js Edgar Link pending
stsec10k202210k2022v3_1.jpg Edgar Link pending
scth-20221231_pre.xml Edgar Link unprocessable
scth-20221231_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
scth-20221231_lab.xml Edgar Link unprocessable
scth_form10k12312022_htm.xml Edgar Link completed
stsec10k202210k2022v3_2.jpg Edgar Link pending
stsec10k202210k2022v3_3.jpg Edgar Link pending
stsec10k202210k2022v3_4.jpg Edgar Link pending
stsec10k202210k2022v3_5.jpg Edgar Link pending
stsec10k202210k2022v3_6.jpg Edgar Link pending
stsec10k202210k2022v3_7.jpg Edgar Link pending